ESC 365 - Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial

HFA Premium Access

Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 2

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Doctor R. Mentz (Durham, US)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Robert Mentz

Duke University Medical Center, Durham (United States of America)

10 presentations

0 follower

9 more presentations in this session

Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial

Speaker: Doctor C. Lam (Singapore, SG)

Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiovascular and non-cardiovascular mortality

Speaker: Ms A. Shahim (Stockholm, SE)

The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?

Speaker: Doctor P. Dewan (Glasgow, GB)

Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Features of changes in the level of profibrotic factors and their relationship with parameters of left ventricular mechanics in epicardial obesity

Speaker: Doctor O. Gritsenko (Barnaul, RU)

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 2

Speakers: Doctor R. Mentz, Doctor C. Lam, Ms A. Shahim, Doctor P. Dewan, Doctor K. Docherty...

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources